Celldex’ admission of defeat sends shares spiraling down

10:51 EDT 17 Apr 2018 | thePharmaLetter

Shares in US biotech Celldex Therapeutics closed 65% down on Monday at $0.76 after the company announced…

Original Article: Celldex’ admission of defeat sends shares spiraling down

More From BioPortfolio on "Celldex’ admission of defeat sends shares spiraling down"